# eBEST

> eBEST is a VC fund in Yongdungpo backing Biotechnology, Pharmaceutical and Health Care. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Yongdungpo, South Korea
- Total investments: 14
- Last investment: Aug 2023
- Lead investor: 7%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ebest-investment-securities-co-ltd/
- Website: http://www.ebestsec.co.kr/
- Facebook: https://www.facebook.com/ebestinvest/

eBest is a brokerage firm.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2M–$7M |
| Series B | $6.4M–$16M |
| Series C | $12M–$21M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 36% |
| Pharmaceutical | 4 | 29% |
| Health Care | 3 | 21% |
| Medical | 2 | 14% |
| Biopharma | 2 | 14% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 36% |
| Seed | 2 | 14% |
| Series C | 2 | 14% |
| Series A | 1 | 7% |
| Series D | 1 | 7% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 10 | 71% |
| Japan | 1 | 7% |
| United States | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Primemas Inc. | Primemas is a semiconductor startup based in New York with an R&D center in Seoul. It specializes in low-cost, high-performance Hub Chiplet SoC modules designed for the emerging chiplet industry. Primemas Hub Chiplets, or "Hublets" use high-bandwidth, low-latency D2D interfaces to achieve seamless infrastructure sharing with custompartner dies, making them a universal choice for a wide variety of markets (CXL, AI, Crypto, Data Analytics). With Primemas Hublets, the cost and time needed to design and manufacture a custom SoC can be reduced by a factor of 10x. | $7M | Seed | Aug 15, 2023 | https://www.primemas.com/ |
| Label AI | LABEL AI is an innovative Web 3 music platform enabling the creation and management of sounds like music and voice through AI and blockchain. Users can generate music for streaming, video backgrounds, games, metaverse, and AI videos, and create and edit voice content. These creations can be onboarded onto the TRACKS platform, where revenue isdistributed via the LABEL AI Sound Protocol. Through blockchain governance, users can own and operate a decentralized AI sound ecosystem.LABEL team builds up an ecosystem that establishes an incubating system, that will purport to provide an easier access to investment / promotion / distribution and improve an unfair profit structure that exists in the current sphere, striving to prevent copyright infringement cases across the industry. The pillars that will be developed inside of the LABEL Value Chain ecosystem are as following:Incubating SystemThe core idea behind the “Incubating System” is that anyone can register their digital course related to the career or job training and education inside of the LABEL. For the course to be eligible for the listing on the platform, it has to go through the voting system, where the votes are governed by the users and the selection process is carried out according to their votes. Once the selection process is over, the selected course will be provided with the investments in LBL tokens, that are contributed by either partner sales platforms, consumers or individual investors. Settlement System through the usage of NFT and Smart Contracts The courses, that have successfully received investments, will be registered as an NFT standard, which will clearly illustrate the share ratio of the ownership according to the contributions of instructors, voters and investors. The information on sales revenue from partner platforms will be released on the NFT Page, and the revenue generated by the course will be accurately distributed based on the NFT Equity Ratio that is registered in the Smart Contract.NFT MarketThe Course Creator, as well as the voters and inventors that have participated in the incubating process, including the selling platform itself and publicist can sell or trade their NFT share ratio in the NFT Market. The presence of the NFT Market enables the NFT owners to quickly liquidate their position and recover some of their expected future profit, whereas buyers can keep getting their stable profit slices continuously. | $2M | Seed | Feb 14, 2022 | http://label.foundation/ |
| Clesson | Clesson is a music edtech company. | $2M | Private Equity | Feb 11, 2022 | https://www.clesson.net/ |
| Wellmarker Bio | Their Company has developed a biomarker-based cancer drugs based on accumulated developmental experience and know-how. They have a new drug development institute including synthetic and bio-research and management support center.Utilizing R&D infrastructure from Asan Medical Center in Seoul Republic of Korea they are focusing on developingnew drugs that overcome resistance of existing therapeutic approaches.Additionally they are focusing on developing first-in-class biomarker-based drugs for medical unmet needs in various cancers such as colon cancer, lung cancer and liver cancer. | $11.8M | Series C | Oct 14, 2021 | http://www.wmbio.co/ |
| Gexval | GEXVal is to help patients and families fighting against orphan and intractable diseases | $6.4M | Series B | Sep 10, 2021 | https://gexval.com/ |
| Deepixel | Deepixel is a visual intelligence tech-startup based on computer vision and machine learning that change how people interact with the digital world by providing a user interface. The company is focused on the development of new way to naturally interface with virtual reality, augmented reality, and mixed reality for fashion and accessory. | $1.7M | Series A | Aug 31, 2021 | http://www.deepixel.xyz |
| April Bio | April Bio is a drug development company that develops antibodies and long-acting biologics. | $21.5M | Series C | Aug 24, 2021 | http://www.aprilbio.com |
| Rznomics | Rznomics Inc. is a South Korean biotechnology company developing RNA-based gene therapies for cancer, genetic, and neurodegenerative diseases. The company focuses on trans-splicing ribozyme and circular RNA technologies, with pipeline candidates targeting liver cancer, glioblastoma, Alzheimer’s disease, and retinal disorders. | $9.4M | Series B | Apr 16, 2021 | http://rznomics.com/ |
| NEXEL | NEXEL is a biotechnology research firm that specializes in the advancement of drugs, biotherapeutics, and iPSC technology. | $15.7M | Series B | Apr 16, 2021 | https://nexel.co.kr |
| Watcha | WATCHA - Launched in AUG 2012, it quickly became Korea’s favorite movie review app - Its core competency lies in personalized recommendation technology - once users rate movie, WATCHA predicts how they will like movies they haven’t yet seen - Now provides the widest and most accurate movie, TV show and book reviews - Launched in Japan in 2015WATCHA PLAY - Launched in JAN 2016 - Subscription VOD service for movie and TV series available on multiple devices including Web, iOS/Android mobile and tablet, Samsung/LG Smart TV, Google Chromecast, Android TV - Provides extremely accurate personalized content recommendation, powered by WATCHA - 75% of content consumed based on recommendationsComment by Apple, App Store Editor Team “Thanks to its large volume of reliable review data collected from users, WATCHA PLAY can recommend contents that perfectly satisfy my taste. Please don’t waste your time in choosing what to watch. Trust WATCHA PLAY and Enjoy tonight” | $17.2M | Series D | Dec 21, 2020 | https://watcha.com |

10 of 14 investments shown.

## Co-investors
- [Korea Development Bank](https://shizune.co/investors/profile/korean-development-bank) — VC Fund, 3 deals together
- [ATP Investment](https://shizune.co/investors/profile/atp-investment) — VC Fund, 2 deals together
- [BNK Venture Capital](https://shizune.co/investors/profile/bnk-venture-capital) — VC Fund, 2 deals together
- [BNK Venture Capital](https://shizune.co/investors/profile/bnk-venture-capital-c3fd) — VC Fund, 2 deals together
- [BSK Investment](https://shizune.co/investors/profile/bsk-investment-7237) — VC Fund, 2 deals together
- [Groom Investment](https://shizune.co/investors/profile/groom-investment) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Reach Capital](https://shizune.co/investors/profile/reach-capital) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [GSV Ventures](https://shizune.co/investors/profile/gsv-acceleration) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [EdTech Investors in South Korea](https://shizune.co/investors/edtech-investors-south-korea)
- [EdTech VC Funds in South Korea](https://shizune.co/investors/edtech-vc-funds-south-korea)
- [Music VC Funds in South Korea](https://shizune.co/investors/music-vc-funds-south-korea)

## FAQ

### What does eBEST invest in?

eBEST invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series B and Seed stage. Most of the 14 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is eBEST's check size?

eBEST typically joins rounds of $2M–$7M at Seed, $6.4M–$16M at Series B and $12M–$21M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds eBEST participates in.

### When did eBEST last invest?

The most recent investment recorded for eBEST closed in Aug 2023. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co